The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery

The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery. The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival. The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981, P < 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807, P = 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290, P = 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438, P = 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs. The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer.